Nanoviricides
NNVC on NYSEAmerican. Market value $37m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 48 funds in all.
Largest holders overall
- Vanguard Capital Management$1mAdded
- Geode Capital Management$298,178Cut
- Connective Capital Management$255,599New
- BlackRock$219,079
- Vanguard Fiduciary Trust$182,054Added
- Renaissance Technologies$177,468Cut
- Miller Financial Services$154,560Added
- UBS Group AG$137,077Cut
- Creative Planning$119,730New
- Susquehanna International Group, LLP$83,650Cut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
No one has reported a stake above 5% since December 2024.
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought or sold on the open market in the last 12 months.
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Nanoviricides’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 28 Sep 2026, plus 1 later 8-K.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“As a result, substantial doubt exists about the Company’s ability to continue as a going concern.”
Show the full paragraph
Management believes that the Company’s cash and cash equivalents balance of approximately $2.8 million, additional capital raised subsequent to June 30, 2026, of approximately $3.4 million net of the placement agent’s fees and offering expenses payable by the Company in a Registered Direct Offerings (“RDO”) of common stock, and the Company’s existing resources, including availability under its $3 million line of credit will not be sufficient to fund the Company’s planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-K. As a result, substantial doubt exists about the Company’s ability to continue as a going concern. Management is actively exploring additional required funding through non-dilutive grants and contracts, partnering, debt or equity financing pursuant to its plan. There is no assurance that we will be successful in obtaining sufficient financing on terms acceptable to us to fund continuing operations.
From the 10-K filed 28 September 2026, Item 1A. Risk Factors. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.